1. Introduction

Commercial Genome Accountability refers to the legal and ethical responsibility of companies, laboratories, biotechnology firms, hospitals, genetic-testing providers, pharmaceutical businesses, and data-processing organizations that collect, analyze, store, license, sell, or otherwise commercially exploit human genomic information.

A genome contains extensive information about an individual's biological characteristics and may reveal information about relatives, ancestry, inherited disease risks, and other sensitive traits. Commercial use of genomic data can support medical research, personalized medicine, drug development, and biotechnology innovation. However, it can also create risks involving privacy violations, discrimination, unauthorized commercialization, misleading medical claims, and misuse of biological samples.

The term Commercial Genome Accountability is best understood as an analytical legal framework, rather than the name of one universally recognized statute or established judicial doctrine. Its requirements arise from multiple areas of law, including data protection, informed consent, medical negligence, consumer protection, intellectual property, contract law, and human-rights principles.

In India, the framework is particularly relevant to genetic-testing companies, biotechnology startups, research institutions, pharmaceutical manufacturers, and businesses that transfer genomic data to third parties or overseas entities.

2. Meaning and essential elements

Privacy and data protection

Organizations must establish a lawful basis for processing genomic data, protect it from unauthorized access, and comply with applicable privacy and data-protection requirements.

Informed consent and transparency

Individuals should receive understandable information about testing purposes, data storage, research use, commercial sharing, and relevant limitations before consenting where consent is required.

Fair commercial use

Companies should not use genomic information beyond applicable legal permissions, misrepresent genetic-test accuracy, or exploit customers through unfair or deceptive practices.

Auditability and liability

Organizations should be able to explain their data practices, document access and transfers, investigate breaches, and provide appropriate remedies when legally responsible for harm.

3. Legal foundations of commercial genome accountability

A. Privacy and confidentiality

Genomic data is unusually sensitive because removing a person's name does not necessarily make their genetic information anonymous. A genomic profile may sometimes be linked to other databases to identify a person or infer information about family members.

A commercial organization should therefore assess:

Whether the data collection and processing have a valid legal basis.

Whether the individual was informed about the intended use.

Whether third-party disclosure is permitted.

Whether security controls and retention limits are appropriate.

Whether data-subject rights, deletion requests, and breach-reporting duties apply.

Privacy accountability is not limited to preventing hackers from accessing a database. It also concerns whether a company had the legal authority to use or share the data in the first place.

B. Informed consent

Consent to undergo a genetic test does not necessarily constitute consent to every subsequent commercial use of the resulting data.

For example, a person may agree to receive a hereditary disease-risk report but not agree to have their genomic data licensed to a pharmaceutical company for unrelated research.

Depending on the applicable law, the provider may need separate, specific, or otherwise legally adequate authorization for secondary uses. Consent must also be assessed in context: a lengthy contract may not adequately communicate a material commercial practice that the customer could not reasonably understand.

C. Commercialization and ownership

Three separate legal questions must be distinguished:

Ownership or control of a physical sample: Who has rights and responsibilities concerning the blood, saliva, tissue, or extracted DNA?

Rights over information: What rights does the individual have regarding the collection, use, disclosure, and correction or deletion of personal genomic data?

Intellectual property: Can a company protect a diagnostic method, engineered molecule, invention, or other qualifying innovation?

These questions do not necessarily have the same answer. Permission to store a biological sample does not automatically authorize unlimited commercial exploitation of all information derived from it. Similarly, a patent over a qualifying invention does not give the patent holder unrestricted ownership of a person's genome.

4. Important case laws

The following judgments provide significant principles for analyzing commercial genome accountability. Some directly concern genetic commercialization, while others establish broader privacy, consent, property, or biotechnology principles that may apply by analogy.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: The Supreme Court considered whether the Indian Constitution protects a fundamental right to privacy.

Judgment: The nine-judge bench unanimously recognized privacy as a fundamental right, grounded in Article 21 and the freedoms guaranteed under Part III of the Constitution.

National Digital Library of India+1

Relevance to commercial genomes:

Genetic information can reveal intimate details about a person's biological identity and health.

Commercial collection or disclosure of such information raises serious privacy concerns.

Restrictions on privacy must satisfy applicable constitutional requirements, including legality and proportionality where relevant.

The judgment provides a constitutional foundation for evaluating intrusive state action involving genetic databases.

Legal principle: The commercialization of genomic information should be assessed with due regard to informational privacy, individual autonomy, and dignity.

Important qualification: Puttaswamy was not a direct ruling on a private genetic-testing company's commercial use of DNA. Its constitutional reasoning is relevant, but a claim against a private company must also identify the applicable statutory, contractual, tort, or other legal basis.

Case 2: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

United States Supreme Court · 569 U.S. 576 (2013)

Facts: Myriad Genetics identified the locations and sequences of the BRCA1 and BRCA2 genes, associated with increased risks of breast and ovarian cancer. It obtained patents that restricted certain competing uses and genetic testing.

Issue: Could naturally occurring human DNA be patented merely because it had been isolated from the body?

Judgment: The Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated. However, synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the Court's reasoning and applicable patent law.

Justia U.S. Supreme Court Center+1

Relevance to commercial genome accountability:

Discovering a naturally occurring human gene does not automatically establish a right to patent it.

Patent claims must distinguish a natural biological discovery from a qualifying invention.

Exclusive patent rights can affect access to genetic testing and competition among laboratories.

A commercial entity must assess whether its claimed invention falls within the applicable patentability standards.

Legal principle: Commercial investment in genomic research does not automatically confer exclusive ownership over naturally occurring human genetic information.

Indian-law qualification: This is a US decision, not binding precedent in India. Its reasoning may be persuasive when discussing the distinction between discovery and invention, but Indian patentability must be determined under the Patents Act, 1970, including the applicable exclusions in Section 3.

Case 3: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120 (1990)

Facts: John Moore's cells were used in research that resulted in a commercially valuable cell line. He alleged that his physician had not adequately disclosed the research and financial interests connected with his treatment.

Issue: Did the patient's allegations establish property-based claims concerning the excised cells, and what duties arose from undisclosed commercial interests?

Judgment: The court rejected Moore's conversion claim concerning the excised cells but allowed other claims, including breach of the physician's disclosure duties and lack of informed consent, to proceed on the relevant allegations.

Genome.gov

Relevance to genomic commercialization:

Biological samples may have substantial commercial value.

The legal position concerning physical specimens is distinct from duties to disclose conflicts of interest.

Medical professionals must appropriately disclose material interests that could affect patient decision-making.

A patient's lack of ownership over a particular research product does not necessarily eliminate other legal claims.

Legal principle: Commercial value derived from human biological material can raise disclosure, consent, and fiduciary-duty questions even when ownership of the resulting research product is not vested in the source individual.

Qualification: Moore concerns California law and is not a universal rule that patients lack ownership rights in all biological materials. Its application in India would require analysis under Indian law and the specific facts.

Case 4: Diamond v. Chakrabarty (1980)

United States Supreme Court · 447 U.S. 303 (1980)

Facts: The dispute concerned whether a genetically engineered microorganism capable of breaking down components of crude oil could be patented.

Judgment: The Court held that the claimed human-made microorganism was patent-eligible subject matter under the US patent statute because it possessed characteristics distinguishable from naturally occurring organisms.

LII / Legal Information Institute

Relevance: This judgment illustrates the legal distinction between an unmodified natural phenomenon and a qualifying human-made biotechnological invention.

A biotechnology company may be able to protect a qualifying engineered product or process, but this does not automatically authorize the company to collect personal genetic data without permission or disregard applicable safety and regulatory requirements.

Legal principle: Patentability and accountability are separate questions. A patent may protect an invention without excusing unlawful data processing, deficient consent, or negligent clinical practices.

Case 5: K.S. Puttaswamy v. Union of India (Aadhaar judgment) (2018)

Supreme Court of India · Aadhaar judgment, 26 September 2018

Facts and issue: The Court examined the Aadhaar framework, including privacy, collection of personal information, authentication, and restrictions on the use of Aadhaar-related data.

Judgment and relevance: The judgment examined the need for legal authority and safeguards when personal information is collected and processed, as well as the proportionality of restrictions on privacy.

Sci API+1

For commercial genomic services, the broader reasoning supports questions such as:

Is the collection of genetic information supported by appropriate legal authority?

Are there meaningful safeguards against misuse?

Is the amount of information collected justified by the stated purpose?

Are disclosures and retention practices consistent with applicable law?

Qualification: Aadhaar information and genomic data are not legally identical. The judgment is relevant for its privacy principles, not because it directly establishes a comprehensive genome-specific regulatory regime.

5. Statutory framework in India

A. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 (DPDP Act) is central to the analysis of digital genomic information, subject to its scope, exemptions, and phased commencement.

The Government notified the DPDP Rules, 2025, and the commencement arrangements provide for different provisions to take effect at different times. As of 2 November 2026, the Act should not be treated as if all its substantive provisions were already in force. The main provisions governing processing and individual rights are scheduled for the 18-month phase following the November 2025 notification.

Press Information Bureau+2

Relevant principles include:

Lawful processing: Determine whether the processing falls within the Act and is legally permitted.

Notice and consent: Where required, explain the purposes of collection and obtain valid consent.

Security safeguards: Protect personal data against unauthorized processing and breaches.

Individual rights: Prepare for applicable rights and obligations as the relevant provisions commence.

Accountability: Maintain appropriate procedures for compliance, complaints, and incident handling.

Genomic data that identifies, or can be linked to, an individual may fall within the Act's definition of digital personal data. The Act does not create a blanket rule that every genomic dataset must always receive a distinct statutory category equivalent to a specially defined category of sensitive personal data.

B. Constitution of India

Articles 14, 19, and 21 may be relevant depending on the circumstances, particularly where governmental action, constitutional rights, or state-linked genetic databases are involved.

Article 14: Protection against constitutionally impermissible arbitrariness and unequal treatment by the State.

Article 19: Relevant freedoms may arise in disputes involving research, expression, or commercial activity, subject to constitutional limitations.

Article 21: Protects life and personal liberty, with privacy recognized as a fundamental right.

These constitutional provisions do not automatically create identical direct constitutional claims against every private biotechnology company.

C. Patents Act, 1970

Indian patent law regulates whether biotechnology inventions qualify for patent protection.

Section 3(c) excludes the discovery of a living thing or non-living substance occurring in nature from patentability. Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, and essentially biological processes for the production or propagation of plants and animals, subject to the precise statutory wording.

The legal assessment must therefore distinguish:

Naturally occurring human genetic sequences.

Engineered biological materials.

Diagnostic methods and laboratory techniques.

Patent claims involving qualifying technical inventions.

A commercial genome business cannot assume that all genetic discoveries, test methods, or biological materials are patentable merely because they have commercial utility.

D. Consumer Protection Act, 2019

Commercial genetic-testing providers may face consumer-protection claims where applicable, particularly in cases involving deficient services, misleading representations, or unfair trade practices.

Examples include:

Advertising a genetic test as certain to predict a disease when it only estimates probability.

Misrepresenting a test's clinical validity or accuracy.

Concealing material limitations of the test.

Charging for services that materially differ from those promised.

Liability depends on the facts, the nature of the service, applicable statutory requirements, and available defenses. A scientifically uncertain result is not automatically evidence of negligence or a consumer-law violation.

E. Medical negligence and informed consent

Where genomic testing is provided through a clinical relationship, ordinary principles of professional negligence, disclosure, and informed consent may apply.

The Supreme Court of India in Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1 examined the requirements for valid medical consent.

The judgment concerned medical treatment rather than commercial genomic databases, but its consent principles are relevant when a provider proposes a materially different procedure or use from the one authorized by the patient.

For instance, consent to a clinical genetic test should not automatically be treated as permission for unrelated research, publication of identifiable genetic information, or commercial licensing where additional authorization is legally required.

6. Civil, regulatory, and other liability

Commercial genome accountability can involve several forms of liability.

These categories may overlap. However, a company is not automatically liable merely because a genetic test produces an unfavorable result, research becomes commercially successful, or a data breach occurs. The relevant legal elements must be established.

7. Practical example: Commercial exploitation of a genetic database

Consider a hypothetical company, Genome Analytics Pvt. Ltd., that collects saliva samples from 50,000 customers to provide ancestry and inherited-disease risk reports.

The company later licenses the genomic profiles to a pharmaceutical manufacturer for drug-development research without clearly disclosing that secondary use.

The legal issues would include:

Purpose and authorization: Did the original terms and applicable law authorize the secondary use?

Privacy: Could the purportedly de-identified records be linked back to individuals?

Transparency: Were customers adequately informed about commercial sharing?

Security: Were access controls, data-transfer safeguards, and retention practices appropriate?

Research governance: Did the activity require additional consent, ethics review, or compliance with research-specific requirements?

Remedies: Depending on the applicable law and evidence, could affected individuals seek a regulatory remedy, contractual relief, or compensation?

The company cannot resolve all these questions merely by asserting that it owns the database. Ownership of a database, permission to process personal data, authority to use physical samples, and rights over research inventions are distinct legal issues.

If the data were properly anonymized, that could reduce some privacy risks, but it would not necessarily resolve questions concerning sample use, contractual promises, research ethics, or other applicable legal restrictions.

8. A proposed accountability model

Although Commercial Genome Accountability is not a single established statutory doctrine, it can be used as a structured compliance model for biotechnology organizations.

1. Consent and purpose documentation

Record the purpose of collection, permitted uses, relevant disclosures, and the legal basis for processing.

2. Data governance

Classify genomic records, restrict access, assess re-identification risks, and establish retention and deletion procedures.

3. Third-party accountability

Assess research partners, data recipients, service providers, and cross-border transfers under applicable requirements.

4. Independent oversight

Use legal reviews, scientific validation, ethics oversight where required, internal audits, and documented complaint procedures.

5. Remediation and responsibility

Investigate complaints, contain breaches, notify relevant parties when required, correct misleading practices, and provide legally appropriate remedies.

9. Critical legal analysis

Three distinctions are essential when applying this framework.

First, privacy is not the same as property. A person may have legally protected interests in genomic information even if the law does not recognize exclusive ownership of every biological sample or research product derived from it.

Second, consent is not the same as unlimited authorization. Consent must be assessed against the purpose, information supplied, governing law, and subsequent use. Whether new consent is necessary depends on the circumstances and applicable legal requirements.

Third, innovation is not immunity from liability. A valid patent or commercially successful discovery does not excuse violations of data-protection law, contractual obligations, consumer law, or professional duties.

The difficult policy question is how to protect individual autonomy and prevent exploitation without unnecessarily restricting legitimate biomedical research. A sound framework should promote scientific progress while requiring transparency, proportionate safeguards, fair commercial practices, and effective remedies.

10. Conclusion

Commercial Genome Accountability is a useful analytical framework for examining the responsibilities of businesses that profit from human genetic information and biotechnology.

The principal judicial authorities discussed here establish complementary legal principles:

Puttaswamy (2017): constitutional privacy and autonomy in India.

Myriad Genetics (2013): limits on patenting naturally occurring human DNA under US law.

Moore (1990): biological-material commercialization and disclosure duties under California law.

Diamond v. Chakrabarty (1980): patentability of a qualifying engineered microorganism under US law.

The 2018 Aadhaar judgment: safeguards and proportionality in the handling of personal information.

Samira Kohli (2008): informed consent in medical treatment.

Taken together, these cases help frame a legal approach in which commercial genomic activity must be evaluated through the distinct requirements of privacy, consent, scientific accuracy, intellectual property, and accountability. They do not, however, establish one universal legal doctrine governing every commercial use of the human genome.

For further research, the most useful next step would be a case-law comparison of Indian, US, and European approaches to genomic privacy, genetic-data commercialization, and corporate liability, with the statutory provisions and relevant judgments examined separately.